Parkinson's disease (PD) is a neurological condition, which affects the brain. Some symptoms of PD are tremors, stiffness, and slowness of movement. The purpose of this study is to assess how safe and effective ABBV-951 is in treating participants with Parkinson's disease in real world setting. ABBV-951 is an approved drug being developed for the treatment of PD in Japan. Approximately 250 adult participants over 15 years with a diagnosis of PD who are prescribed ABBV-951 by their physicians will be enrolled in this study across Japan. Participants will receive ABBV-951 as prescribed their physician and followed for 52 weeks. There is expected to be no additional burden for participants in this trial. Study visits may be conducted on-site or virtually as per standard of care.
Study Type
OBSERVATIONAL
Enrollment
250
Saiseikai Matsuyama Hospital /ID# 276259
Matsuyama, Ehime, Japan
National Hospital Organization Asahikawa Medical Center /ID# 269115
Asahikawa, Hokkaido, Japan
Hakodate Municipal Hospital /ID# 276757
Hakodate-shi, Hokkaido, Japan
Ryugasaki Saiseikai Hospital /ID# 264435
Ryūgasaki, Ibaraki, Japan
University of Tsukuba Hospital /ID# 268353
Tsukuba, Ibaraki, Japan
Okatsu Hospital /ID# 262781
Kagoshima, Kagoshima-ken, Japan
University Hospital Kyoto Prefectural University of Medicine /ID# 267445
Kyoto, Kyoto, Japan
Sendai Nishitaga National Hospital /ID# 268349
Sendai, Miyagi, Japan
Fujimoto General Hospital /ID# 277287
Miyakonojo-shi, Miyazaki, Japan
Shiga University of Medical Science Hospital /ID# 265637
Ōtsu, Shiga, Japan
...and 7 more locations
Percentage of Participants Experiencing Infusion Site Infections
Percentage of participants with infusion site infections following the commencement of ABBV-951 will be assessed.
Time frame: Up to 52 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.